Cancer Drug Repurposed for HHT

This is a U.S. news story, published by ScienceDaily, that relates primarily to Pamela Hodges news.

U.S. news

For more U.S. news, you can click here:

more U.S. news

Pamela Hodges news

For more Pamela Hodges news, you can click here:

more Pamela Hodges news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

ScienceDaily news

For more news from ScienceDaily, you can click here:

more news from ScienceDaily

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

Hereditary hemorrhagic telangiectasia

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest common inherited bleeding disorder news, blood cancer multiple myeloma news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

hereditary bleeding disorder

ScienceDaily

•

Clinical trial successfully repurposes cancer drug for hereditary bleeding disorder

Summary

Nutrition label

76% Informative

Hereditary hemorrhagic telangiectasia ( HHT ) affects approximately 1-in-5,000 people and can have life-threatening complications, but there are currently no U.S. FDA -approved drugs to treat HHT .

Pomalidomide, currently approved to treat multiple myeloma, was found to be safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder.

"This success would not have been possible without the efforts of Pamela Hodges , NP , PhD and the incredible research nurses, coordinators, and associates within the Mass General Cancer Center .

It has also been my great pleasure to work with Dr. Keith McCrae at the Cleveland Clinic to contribute to this multicenter effort.

As a multisystem disease, HHT is very much a team sport.".

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive